0001493152-26-022796
SEC filingKairos Pharma reported a deeper operating loss and increased cash outflow from operations in Q1 FY2026, reflecting continued pre-revenue investment; diluted EPS remained unchanged despite the widening loss, consistent with the company’s capital structure dynamics.
Operating income for Q1 FY2026 was -$1.7M, a 33.5% decline from -$1.3M in Q1 FY2025. Net income followed a similar trajectory at -$1.7M, down 31.1% from -$1.3M. These results reflect the absence of revenue and the continuation of core operating activities required to advance the company’s development programs. The consistency between operating and net income magnitudes indicates minimal non-operating income or expense impact during the quarter.
Diluted EPS remained unchanged at -$0.08 year-over-year. While absolute losses widened, the per-share metric did not deteriorate — a dynamic attributable to changes in weighted-average diluted shares outstanding. Management commentary references unregistered equity sales, including ATM and prefunded warrant activity, which influence share count; however, specific issuance amounts or timing are not numerically supported in the authoritative financial packet and therefore are not quantified here.
Management states it anticipates increasing general and administrative expenses as headcount expands to support business operations. This expectation is explicitly tied to operational scaling, not speculative growth assumptions. Separately, the filing warns that failure to secure additional funding would exhaust available capital resources sooner than expected — a direct implication of the current negative operating cash flow profile and full deployment of IPO proceeds.